Recently-developed semaglutide offers weight loss
Semaglutide was developed in 2012 by the Novo Nordisk company. It mimics the action of incretin glucagon-like peptide – 1 (GLP-1). It reportedly increases insulin secretion which removes excess sugar from the blood. It is still under patent and offered to the market as several trade name products; Ozempic (injection),...
This content is for 30 Day Free Trial, 3 Months for 99 Cents, and One Year Subscription subscribers only.
Register
Register
Already a member? Log in here